New Market Study Published: Vermillion, Inc. (VRML) - Product Pipeline Analysis, 2013 Update
Vermillion, Inc. (VRML) is a molecular diagnostics company. The company offers innovative method to detect, monitor and manage the treatment of gynecologic cancers and other related diseases. It operates under one reportable segment, Novel Diagnostic Tests. VRML's Novel Diagnostic Tests segment develops diagnostic products for the identification of three diseases, namely, peripheral artery disease (PAD), thrombotic thrombocytopenic purpura (TTP), and ovarian cancer. The company offers products such as ovarian tumor triage test (OVA1), OVA2 and VASCLIR. It develops novel blood...
View full press release